0.85%
6.00%
-21.60%
-24.93%
53.99%
12.76%
-28.52%
AI Spotlight on AGIO
Company Description
Agios Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of medicines in the field of cellular metabolism and adjacent areas of biology.The company offers PYRUKYND (mitapivat) an activator of both wild-type and a variety of mutant pyruvate kinase, PK, enzymes for the treatment of hemolytic anemias; and AG-946 that is in Phase I clinical study for treating hemolytic anemias and other indications.Agios Pharmaceuticals, Inc.
was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.
Market Data
| Last Price | 34.83 |
| Change Percentage | 0.85% |
| Open | 34.6 |
| Previous Close | 34.54 |
| Market Cap ( Millions) | 1987 |
| Volume | 121653 |
| Year High | 62.58 |
| Year Low | 22.41 |
| M A 50 | 42.69 |
| M A 200 | 42.67 |
Financial Ratios
| FCF Yield | -16.62% |
| Dividend Yield | 0.00% |
| ROE | 70.20% |
| Debt / Equity | 3.74% |
| Net Debt / EBIDTA | 47.91% |
| Price To Book | 1.22 |
| Price Earnings Ratio | 2.94 |
| Price To FCF | -6.02 |
| Price To sales | 60.43 |
| EV / EBITDA | -4.45 |
News
- Jan -09 - FDA Accepts Agios' sNDA for Pyrukynd in Thalassemia
- Jan -08 - Cardurion Pharmaceuticals Appoints Charlotte Newman as Chief Business Officer
- Jan -03 - Agios to Present at the 43rd Annual J.P. Morgan Healthcare Conference on January 15, 2025
- Dec -18 - European Commission Adopts Positive Decision for Orphan Medicinal Product Designation of Agios' Mitapivat in Sickle Cell Disease
- Dec -10 - Here's Why Agios Stock Plummeted More Than 20% on Monday
- Dec -08 - Agios Presents Positive Results from Phase 3 ENERGIZE-T Study of Mitapivat at ASH 2024 and Provides Regulatory Update on Mitapivat
- Dec -04 - 4 Medical Product Stocks to Buy From a Prospective Industry
- Nov -26 - Is Agios Pharmaceuticals (AGIO) Stock Outpacing Its Medical Peers This Year?
- Nov -05 - Agios to Present New Data on Mitapivat and Tebapivat in Rare Blood Disorders at 66th ASH Annual Meeting and Exposition
- Nov -01 - AGIO's Q3 Earnings Miss Mark, Revenues In Line, Stock Down
- Oct -31 - Agios Pharmaceuticals, Inc. (AGIO) Q3 2024 Earnings Call Transcript
- Oct -31 - Agios Pharmaceuticals (AGIO) Misses Q3 Earnings and Revenue Estimates
- Oct -31 - Agios Reports Business Highlights and Third Quarter 2024 Financial Results
- Oct -17 - Agios to Webcast Conference Call of Third Quarter 2024 Financial Results on October 31, 2024
- Sep -12 - FDA Grants Orphan Drug Tag to AGIO's Tebapivat for Rare Cancer
- Sep -11 - Agios Announces FDA Orphan Drug Designation Granted to Tebapivat (AG-946) for Treatment of Myelodysplastic Syndromes (MDS)
- Sep -05 - Agios to Present at the 2024 Cantor Global Healthcare Conference on September 18, 2024
- Aug -27 - Agios' Mitapivat: A Potential Blockbuster In Thalassemia Treatment
- Aug -06 - Agios to Receive $1.1 Billion in Milestone Payments Following FDA Approval of Vorasidenib
- Aug -02 - AGIO Q2 Earnings Lag, Stock Down on Missing Pediatric Study Goal
Business Breakdown
Expected Mid-Term Growth
Segment n°1 -> Medicines for Cellular Metabolism
Expected Growth : 12.4 %
What the company do ?
Agios Pharmaceuticals' medicines for cellular metabolism target cancer and rare genetic disorders by regulating cellular metabolism, addressing underlying disease biology.
Why we expect these perspectives ?
Growing demand for targeted cancer therapies, increasing prevalence of rare genetic disorders, and Agios' innovative approach to regulating cellular metabolism drive market growth.
Agios Pharmaceuticals, Inc. Products
| Product Range | What is it ? |
|---|---|
| TIBSOVO | TIBSOVO is an isocitrate dehydrogenase-1 (IDH1) inhibitor indicated for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) with an IDH1 mutation. |
| IDHIFA | IDHIFA is an isocitrate dehydrogenase-2 (IDH2) inhibitor indicated for the treatment of adult patients with relapsed or refractory AML with an IDH2 mutation. |
| ivosidenib | Ivosidenib is an IDH1 inhibitor being developed for the treatment of AML and other blood cancers. |
| enasidenib | Enasidenib is an IDH2 inhibitor being developed for the treatment of AML and other blood cancers. |
Agios Pharmaceuticals, Inc.'s Porter Forces
Threat Of Substitutes
Agios Pharmaceuticals, Inc. operates in a niche market with limited substitutes, but there are ongoing research and development efforts to discover new treatments, which could potentially threaten the company's products.
Bargaining Power Of Customers
Agios Pharmaceuticals, Inc. sells its products primarily to wholesalers, distributors, and specialty pharmacies, which have limited bargaining power due to the company's strong product portfolio and limited alternatives.
Bargaining Power Of Suppliers
Agios Pharmaceuticals, Inc. relies on a limited number of suppliers for raw materials and services, which could lead to some bargaining power, but the company's strong relationships and contracts mitigate this risk.
Threat Of New Entrants
The biotechnology industry has high barriers to entry, including significant research and development costs, regulatory hurdles, and the need for specialized expertise, making it difficult for new entrants to compete with Agios Pharmaceuticals, Inc.
Intensity Of Rivalry
Agios Pharmaceuticals, Inc. operates in a highly competitive market with several established players, and the company faces intense competition for market share, pricing, and innovation.
Capital Structure
| Value | |
|---|---|
| Debt Weight | 8.15% |
| Debt Cost | 4.24% |
| Equity Weight | 91.85% |
| Equity Cost | 7.91% |
| WACC | 7.61% |
| Leverage | 8.88% |
Agios Pharmaceuticals, Inc. : Quality Control
Agios Pharmaceuticals, Inc. passed 4 out of 9 key points:
Historical Valuation
Price/Earnings Ratio
Margin Valuation
Peers Valuation
Competitors
| Company | Rational |
|---|---|
| CRNX | Crinetics Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. Its lead product candidate is Paltusotine, … |
| SRPT | Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It … |
| CYTK | Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily … |
| RNA | Avidity Biosciences, Inc., a biopharmaceutical company, engages in the development of oligonucleotide-based therapies. It develops antibody oligonucleotide conjugates (AOC) that are designed to treat a range of serious diseases. The … |
| SWTX | SpringWorks Therapeutics, Inc. acquires, develops, and commercializes medicines for underserved patient populations suffering from rare diseases and cancer. Its lead product candidate is nirogacestat, an oral small molecule gamma secretase … |
Peers Metrics
DCF BETA
Expected Cash-Flows
Scoring Insights
Peers Group Analysis
🥇
Agios Pharmaceuticals
A-Score
1-Year Total Return ->
🥈
Avidity Biosciences
A-Score
1-Year Total Return ->
🥉
Crinetics Pharmaceuticals
A-Score
1-Year Total Return ->
4
Sarepta Therapeutics
A-Score
1-Year Total Return ->
5
Cytokinetics
A-Score
1-Year Total Return ->
6
